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Abstract
Background: The greater saphenous vein is frequently used as a conduit for coronary artery bypass grafting
(CABG). Previously, veins were most often harvested using open vein harvesting (OVH), however, endoscopic vein
harvesting (EVH) techniques have become increasingly popular. Nevertheless, the long-term cost-effectiveness of
EVH remains unknown. The present study estimated the long-term cost-effectiveness of EVH versus OVH for
CABG.
Methods: A Markov model was developed to estimate life-time costs (UK Pounds Sterling) and quality adjusted
life-years (QALYs) with comparative results presented as incremental cost-effectiveness ratios (ICERs). Costs and
probabilities of events in the OVH group were mainly drawn from a previously published study. Resource
consumption and event probabilities in the EVH group were estimated using a meta-analysis to reflect the best
available evidence. Parameter uncertainty was assessed using both one-way sensitivity analyses and probabilistic
sensitivity analyses.
Results: The life-time cost/QALY was £8219 rendering EVH cost-effective compared to OVH. Sensitivity
analyses showed that EVH was cost-effective in 60.4% of simulations at a threshold of £30 000/QALY, reflecting a
large uncertainty in the point estimate of the ICER. The main causes of uncertainty were the time-horizon and the
event rates of major clinical events in the treatment groups.
Conclusions: Current evidence indicates that EVH is cost-effective for harvesting saphenous vein segments for
CABG compared to OVH. Further studies on long-term clinical outcomes are needed to reach a more precise cost-
effectiveness estimate.
Keywords: CABG; Venous grafts; Endoscopy/endoscopic
procedures; Health economics; Quality of life; Postoperative care
Introduction
The short-term effectiveness and long-term safety of endoscopic
vein harvesting (EVH) versus traditional open vein harvesting (OVH)
of saphenous vein conduits for coronary artery bypass grafting
(CABG) has been investigated rigorously. Meta-analysis of the clinical
evidence show that EVH is a short-term benefit as leg wound
morbidity, infections, and pain is reduced without compromising the
long-term safety as no differences were observed in the recurrence of
chest pain, myocardial infarctions, and all-cause mortality [1-3].
Previous economic evaluations of EVH versus OVH have looked at
costs and outcomes five to six weeks postoperatively [4,5]. Such a short
time-horizon is suitable for an economic evaluation if costs and
outcomes can be considered equal between treatment groups after the
period in which they are compared [6]. Still, no studies have estimated
the long-term (e.g. life-time) cost-effectiveness of EVH compared to
OVH although several reviews have called for a more rigorous cost-
effectiveness analysis [1,7,8]. Therefore, the present study estimated
both the short-term and the life-time cost-effectiveness of EVH of
saphenous vein as a conduit for CABG using total endoscopic methods
compared to OVH using a single continuous incision. This was done
to provide essential information for the decision about vein harvesting
method and to exemplify the importance of choosing the appropriate
time horizon in cost-effective analysis.
Materials and Methods
Model overview
A decision-analytic model was developed to estimate costs and
quality adjusted life-years (QALYs) from the perspective of the Danish
Healthcare System. The model was constructed as a Markov model
with a cycle length of three months, see Figure 1 and the figure legend
for a description of the model (Figure 1). The cohort was CABG
patients aged 65 years and 80% male gender. The base-case model
captured life-time costs and QALYs while an alternative scenario
considered costs and QALYs within three months postoperatively. All
costs and QALYs accrued beyond the first year were discounted using
an annual rate of 3.5% [9].
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Figure 1: Structure of decision-analytic model. The postoperative
course for patients treated with coronary artery bypass grafting
using the saphenous vein as a conduit harvested by endoscopic or
open technique is modelled in this Markov model. All patients
enter the model in the health state “Asymptomatic” symbolizing
that the symptoms of coronary artery disease disappeared following
surgery. Cycles represent health states while boxes represent events
which may occur in the health state which has an arrow leading to
it. The health state “Repeat Revascularization” does not have an
arrow leading back into the health state which means that patients
only stay in this health state for a single cycle (three months). The
stippled lines indicate that patients exit to the side where they
entered.
Event probabilities
As recommended by international guidelines for cost-effectiveness
analysis [10]; the estimates of treatment effectiveness are based on the
formal evidence syntheses of a meta-analysis [1]. Event probabilities
for the Markov model are shown in Table 1. A Danish randomized
trial was used to calculate event probabilities in the OVH group [11].
Event probabilities in the EVH group were then estimated by utilizing
the odds ratios and rate ratios from a meta-analysis [1]. The 95%
confidence intervals (CIs) of the odds ratios and rate ratios were
utilized to estimate the parameter uncertainty. The mortality rate for
the patients in the health state “Asymptomatic” was modelled using
Danish life tables while patients in health states “Recurrence of Chest
Pain”, “Myocardial Infarction” and “Repeat Revascularization” were
assumed to have a higher mortality rate [12-16]. In both treatment
groups it was assumed that patients with recurrence of chest pain had
a hazard ratio for all-cause mortality of 1.29 (95% CI 0.89 to 1.87)
compared to asymptomatic CABG patients [12,15]. Likewise, it was
estimated that patients experiencing a myocardial infarction or a
repeat revascularization had a hazard ratio for all-cause mortality of
7.82 compared to asymptomatic CABG patients [12,16].
QALYs
All health states in the Markov model were assigned a health-related
quality of life (HRQoL) value and the time spent in each health state
was multiplied with the HRQoL value to calculate QALYs. To estimate
HRQoL values for patients during the first three months
postoperatively, a mapping model was utilized [17]. Pain intensity and
mobility problems measured on visual analogue scales (VASs) were
drawn from the best available evidence and mapped to Danish
EQ-5D-3L index scores to obtain the difference in HRQoL [1,18]. The
input for estimating short-term effectiveness, i.e. during the first cycle
of the Markov model, is summarized in Table 2. In the Markov model
the HRQoL values for the chronic conditions were drawn from Danish
and American community based preference weights [19,20].
Temporary HRQoL decrements for repeat revascularization were
drawn from a previous cost-effectiveness comparing CABG and
stenting [21]. In the Markov model the HRQoL for health states other
than “Asymptomatic” were estimated using the decrements shown in
Table 3. For an example, the mean HRQoL in the health state
“Myocardial Infarction” in the 20th cycle, i.e. five years
postoperatively, would be 0.87-5*0.0008-0.148 = 0.718.
Costs
The mean resource consumption was combined with the unit costs
to estimate the total cost per patient. The resource consumption in the
OVH group was mainly estimated from a Danish randomized trial
[11]. The summary statistics from a meta-analysis was used to estimate
the resource consumption in the EVH group [1]. The base-case
analysis assumes that surgeons are trained in EVH and that the wards
have already purchased the video-equipment. As such, the base-case
analysis views the cost of video equipment and training as sunk costs
and does not include these in the analyses. To estimate the unit costs
of repeat revascularizations it was assumed that 42.9% of these were
performed as CABGs and the remaining as percutaneous coronary
interventions. Estimates of resources consumed are summarized in
Table 4.
All costs were measured in 2014 values of Danish Crowns and
subsequently reported in Great British Pound Sterling (£1 GBP = 9.16
DKK). In the absence of information about the parameter uncertainty
in unit costs an alpha and a beta were approximated assuming a
standard error of ± 10% of the mean. Unit costs drawn from previous
studies were inflated to 2014 values using a yearly inflation rate of 2%.
All unit costs are shown in Table 5.
Analyses
Two scenarios were constructed to investigate the cost-effectiveness
of EVH compared to OVH. The two scenarios were based on two
different interpretations of the long-term clinical outcomes following
EVH and OVH. The base-case analysis applied a Bayesian
interpretation of the uncertainty in the data. This interpretation of
clinical evidence is the default in health economic evaluations [22]. It
entails perceiving the point estimate as our best available guess of the
parameter value and the CI as a range which the parameter has a 95%
probability of lying within. The alternative scenario assumes that the
existing evidence confirms non-inferiority of EVH compared to OVH
regarding the long-term clinical endpoint considered in Table 2. In
this alternative scenario the model assumes no long-term differences
in the recurrence of chest pain, myocardial infarction, repeat coronary
angiography, repeat revascularization, or death; i.e. odds ratios and
rate ratios presented in Table 1 are replaced by 1.00 (95% CI: 1.0; 1.0).
The alternative scenario is therefore a comparison of costs and QALYs
within the first three month postoperatively.
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In each scenario the cost-effectiveness of EVH compared to OVH
was calculated as the incremental cost-effectiveness ratio (ICER). The
ICER expresses the expected additional cost of obtaining one
additional QALY. To capture the uncertainty in the estimation of the
ICER, one-way sensitivity analyses were conducted. The five most
important parameters in the one-way sensitivity analyses were
presented in Tornado diagrams. To assess the joint uncertainty in all
parameters, probabilistic sensitivity analysis was conducted using
second order Monte Carlo simulation. Based on the output cost-
effectiveness acceptability curves (CEACs) were drawn. The CEACs
were used to assess the probability of EVH being cost-effective
compared to OVH at increasing threshold values [22]. The UK
threshold of £30 000/QALY was used to assess the cost-effectiveness of
EVH compared to OVH [9]. The decision-analytic model was
developed in Microsoft Excel 2010 (Microsoft Corporation, Redmond,
Washington, USA).
Probability(transition to| transition from) Expected Value in OVHgroup [Source] Expected Value in EVH group (95% CI) [Source] Distribution
*
P(Chest pain | Asymptomatic) until 5 years 0.0286 [28] 0.0280 (0.0180; 0.0436) [1] Lognormal
P(Chest pain | Asymptomatic) after 5 years 0.0028 [28] 0.0028 (0.0018; 0.0044) [1] Lognormal
P(MI | Asymptomatic) until 0.25 years 0.0292 [29] 0.0328 (0.0215; 0.0496) [1] Lognormal
P(MI | Asymptomatic) from 0.25-5 years 0.0029 [15,29] 0.0033 (0.0022; 0.0051) [1] Lognormal
P(MI | Asymptomatic) after 5 years 0.0011 [15] 0.0012 (0.0008; 0.0019) [1] Lognormal
P(MI | Chest pain) until 5 years 0.0083 [15] 0.0093 (0.0061; 0.0142) [1] Lognormal
P(MI | Chest pain) after 5 years 0.0033 [15] 0.0037 (0.0024; 0.0057) [1] Lognormal
P(Death | Asymptomatic) until 0.25 years 0.0317 [11] 0.0293 (0.0244; 0.0352) [1] Lognormal
P(Death | Asymptomatic) after 0.25 years Life-table [12] RR of all-cause mortality applied to life-table [1] Lognormal
P(Repeat Revascularization | Chest pain) 0.0124 [15] 0.0150 (0.0127; 0.0176) [1] Lognormal
P(Repeat Revascularization | MI) 0.0310 [30] 0.0373 (0.0316; 0.0439) [1] Lognormal
P(Coronary Angiography | Chest pain) 0.0070 [30] 0.0074 (0.0047; 0.0117) [1] Lognormal
P(Coronary Angiography | MI) 0.0070 [30] 0.0074 (0.0047; 0.0117) [1] Lognormal
CI = confidence interval; EVH = endoscopic vein harvesting; MI = myocardial infarction; OVH = open vein harvesting; P = probability; RR = rate ratio; *The distribution
is the distribution applied to the odds ratios and rate ratios from the meta-analysis.
Table 1: Transition probabilities for the Markov model
Quality of life outcome Expected Value in OVH group (95% CI)[Source]
Expected Value in EVH group (95% CI)
[Source] Distribution
Non-preference-based measures of health mapped
Pain on a VAS at day 5, mm 28.7 [17] 13.9 (4.2; 23.7) [1,17] Normal
Mobility on a VAS at day 5, mm 36.0 [18] 12.0 [18] Fixed
Pain on a VAS at day 30, mm 16.1 [17] 13.3 (10.1; 16.5) [1,17] Normal
Mobility on a VAS at day 30, mm 30.0 [18] 2.0 [18] Fixed
Health-related quality of life estimates for patients in the “Asymptomatic” health state
Baseline 0.756 (0.727; 0.785) [17] 0.756 (0.727; 0.785) [17] Normal
Postoperative day 5 0.636 (0.607; 0.665) [17] 0.685 (0.655; 0.715) [1,17,18] Normal
Postoperative day 30 0.785 (0.756; 0.815) [17] 0.809 (0.780; 0.840) [1,17,18] Normal
Three months postoperative 0.87 [31] 0.87 [31] Fixed
CI = confidence interval; Endoscopic vein harvesting; OVH = open vein harvesting; VAS = visual analogue scale
Table 2: Health-related quality of life estimates during the first cycle of the Markov model
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Health states Expected Value in both group(95% CI)[Source] Distribution
Reduction for myocardial
infarction -0.148 (-0.186; -0.109) [20] Normal
Reduction for chest pain -0.168 (-0.205; -0.130) [20] Normal
Reduction per additional year -0.0008 (-0.001; -0.0006) [19] Normal
Temporary reduction for
repeat revascularization by
percutaneous coronary
intervention
-0.04 (-0.05; -0.03) [21] Normal
Temporary reduction for
repeat revascularization by
coronary artery bypass
grafting
-0.09 (-0.12; -0.07) [21] Normal
CI = confidence interval
Table 3: Health-related quality of life decrements used in health states
of the Markov model
Type of resource
consumption
Expected
Value in OVH
group[Source]
Expected Value in EVH
group (95% CI)[Source]
Distribution
P(Single use
equipment) 0 1 Fixed
Duration of surgery,
minutes 216 [11] 231 (219; 243) [1,11] Normal
Length of stay in
intensive care unit,
days
2.79 [1] 2.84 (2.57; 3.10) [1,11] Normal
Length of stay in
ward, days 11.5 [4] 11.0 (10.5; 11.4) [1,4] Normal
P(Beside leg wound
revision) 0.020 [11]
0.009 (0.005; 0.015)
[1,11] Lognormal
P(Leg wound
revision in operating
room)
0.010 [11] 0.004 (0.003; 0.007)[1,11] Lognormal
P(Visit from home
care nurse) 0.063 [11]
0.006 (0.003; 0.014)
[1,11] Lognormal
No. of visits per
patient 7.5 [11] 7.5 [11] Fixed
P(Visit to general
practitioner) 0.143 [11]
0.046 (0.028; 0.074)
[1,11] Lognormal
No. of visits per
patient 4.3 [11] 4.3 [11] Fixed
P(Antibiotic
treatment) 0.095 [11]
0.026 (0.020; 0.034) [1,
11] Lognormal
P(Readmission) 0.016 [11] 0.010 (0.007; 0.014)[1,11] Lognormal
CI = confidence interval; EVH = Endoscopic vein harvesting; OVH = open vein
harvesting; P() = probability of resource being consumed
Table 4: Resource consumption
Description of resource Mean [Source] Distribution (Alpha;Beta)
Single use equipment £504 [4] Gamma (100; 5.04)
Duration of surgery, per minute £14.6 [5] Gamma (100; 0.15)
Length of stay in intensive care
unit, per day £2550 [32] Gamma (100; 25.5)
Length of stay in ward, per day £569 [32] Gamma (100; 5.69)
Leg wound revision without
general anesthesia £147 [4] Gamma (100; 1.47)
Leg wound revision in general
anesthesia £643 [4] Gamma (100; 6.43)
Readmission £2509 [33,34] Gamma (100; 25.1)
Visit from home care nurse £52.5 [4,35,36] Gamma (100; 0.53)
Visit to general practitioner £41.5 [37] Gamma (100; 0.42)
Course of antibiotic treatment £48.5 [4] Gamma (100; 0.49)
Transition cost to the “Myocardial
Infarction” state £6861 [33,34] Gamma (100; 68.6)
Transition cost to the “Coronary
Angiography” state £334 [38] Gamma (100; 3.34)
Transition cost to the “Repeat
Revascularization” state £13 880 [33,34] Gamma (100; 139)
Transition cost to the “Death” state £1556 [33,34] Gamma (100; 15.6)
Three month healthcare costs in
the “Asymptomatic” state £344 [39] Gamma (136; 2.35)
Three month healthcare costs in
the “Myocardial Infarction” state £939 [39] Gamma (17; 51.2)
Three month healthcare costs in
the “Recurrence of Chest Pain”
state
£779 [40] Gamma (6.24; 125)
Table 5: Unit costs of resources consumed
Results
In the base-case analysis, EVH was cost-effective compared to
OVH. EVH had an estimated incremental cost of £1325 per patient
and an incremental effectiveness of 0.1612 QALY per patient, i.e. the
ICER was £8219/QALY. The probabilistic sensitivity analysis reviled
that the cost-effectiveness results from the base-case analysis contained
a large uncertainty around the ICER. In the base-case analysis, EVH
had a 60.4% probability of being cost-effective at £30 000/QALY
threshold. The probability of EVH being cost-effective becomes 63.2%
at a threshold of £100 000/QALY. One-way sensitivity analyses
showed that the rate ratio for long-term all-cause mortality was the
most important parameter for the incremental effectiveness of
treatments. Likewise, the odds ratio of recurrence of chest pain was the
parameter with the largest influence on the incremental cost of
treatments. The remaining parameters identified as important for
incremental cost and effectiveness are shown in the Tornado diagrams
in Figure 2.
In the alternative scenario the ICER was £93 419/QALY and
probabilistic sensitivity analysis showed a 20.2% probability of EVH
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being cost-effective at the £30 000/QALY threshold. The alternative
scenario showed an incremental QALY gain of 0.0048 QALY per
patient within three months postoperatively. The incremental cost at
three months postoperatively was £444 per patient.
Figure 2: Tornado diagrams for the base-case analysis. The top
panel shows the five parameters with the largest influence on the
incremental quality adjusted life-years (QALYs) gained using
endoscopic vein harvesting. Likewise, the bottom panel shows the
five most important parameters in the estimation of incremental
costs. The grey boxes indicate the deviation in the expected
incremental value which the upper- and lower-limit values of the
parameter will produce.
Discussion
The present study showed that EVH of saphenous vein segments
for CABG was cost-effective compared to OVH. Although the
economic evaluation is based on the best evidence currently available,
i.e. a meta-analysis, the result is uncertain [1]. The base-case showed a
large uncertainty in the cost-effectiveness result which was mainly
attributed to the uncertainties in differences of long-term event-rates
of major clinical event. To accommodate that some clinicians assume
that the harvesting methods are completely equal in terms of long-
term event-rates of major clinical events; an alternative scenario only
considered costs and QALYs within three months postoperatively.
Under this assumption, EVH was not cost-effective compared to
OVH. The main difference between the base-case and the alternative
scenario is that the QALY gain is much larger in the base-case than in
the alternative scenario. The best evidence currently available on long-
term outcomes show a slight survival benefit of using EVH compared
to OVH. Although this difference is not statistically significant, the
base-case applies the point-estimate as it is the current best evidence
[1].
While the present study investigated the cost-effectiveness of EVH
from the Danish health system’s perspective, many European
cardiothoracic wards might be more concerned with the question of
how technologies such EVH impact their budget. We found no
evidence that costs, at a departmental level, are reduced by using EVH
rather than OVH. As such, EVH will increase spending at departments
of cardiothoracic surgery. However, the additional money spent on
EVH can be considered ‘good value for money’ as our analysis showed
that EVH is cost-effective compared to OVH from the Danish
healthcare system’s perspective. To assess whether this result is
transferable to other jurisdictions it is ideal to perform a formal
evaluation using one of several tools to assess transferability [23-25]. It
should be noted that the decision analytic model was informed with
data from a meta-analysis which included published data from a
variety of countries and that the results of the present economic
evaluation therefore is likely to be generalizable to a number of
jurisdictions.
Two studies have investigated the short-term cost-effectiveness of
EVH or minimal invasive vein harvesting compared to OVH [4,5].
Rao et al. performed decision analytic modeling and estimated that
minimal invasive vein harvesting was cost-effective compared to
conventional harvesting within six weeks postoperatively [5]. In a cost-
effectiveness analysis alongside a randomized trial, Oddershede et al.
concluded that EVH was not cost-effective compared to OVH within
the first five weeks postoperatively [4]. Both previous studies estimated
the short-term QALY gain using mapping methods which were not
based on a statistical algorithm. As such, large differences in short-
term incremental QALYs could be expected. Rao et al. estimated a gain
of 0.0232 QALY within six weeks postoperatively and Oddershede et
al. estimated a gain of 0.0027 QALY within five weeks postoperatively.
The present study estimated the incremental QALY within three
months postoperatively using a published mapping algorithm and
found an incremental gain of 0.0048 QALY. These inconsistent
estimates illustrate the need for trial-based investigations of short-term
QALY gains. Fortunately, two forthcoming randomized controlled
trials will be collecting information on HRQoL until two years
postoperatively [26,27].
Limitations
Although the present study is based on the current best available
evidence, it would have benefitted greatly from more data on the long-
term occurrence of major clinical events. The uncertainties in the odds
ratios and rate ratios for occurrence of major clinical events were the
main reasons for the uncertainties in incremental costs and QALYs.
In addition, the economic evaluation performed in this study did
not include costs of training surgeons in the use of EVH and the cost
of the video equipment. This means that the analyses inform the
decision of whether a Danish ward for cardiothoracic surgery should
continue to use EVH or switch back to OVH. If decision makers are
interested in assessing the cost-effectiveness of changing from their
current use of OVH to EVH, an additional cost of $93.21 US dollar
should be expected in the EVH group [4].
Furthermore, the present study is limited by the fact that it did not
consider costs from a societal perspective. The narrow healthcare
sector perspective means that potential saving for the patients on
analgesics, transportation, etc. have been overlooked. More so, it is
reasonable to believe that EVH might enable some patients to return
to work a bit sooner than OVH. Any difference in productivity is not
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included in the analysis when a healthcare sector perspective is
applied. It is, however, unlikely that these matters would have a large
impact on the results.
Another important limitation in the present study is the fact that
extrapolations had to be performed to estimate life-time costs and
QALYs. One of the important implications of such extrapolations is
that is based on the best current knowledge about the long-term
patency of grafts harvested by EVH and OVH. Although, some studies
have published results on long-term outcomes following EVH and
OVH most were not RCTs and none had more than 5 years follow-up
[1]. As such, more RCT designed to provide long-term data are needed
to assess if there are equivalency patency of graft following EVH and
OVH. In addition, this will help to reduce the uncertainty in the
extrapolations that must be performed. Extrapolation is a necessary
evil in cost-effectiveness research and we based our assumptions on
the best available evidence [1], as recommended by current guidelines
for economic evaluations [10].
In conclusion, the current evidence indicates that EVH is the cost-
effective method for harvesting saphenous vein segments for CABG.
However, if equivalency in long-term clinical outcomes between
harvesting methods is assumes, EVH is unlikely to be cost-effective
compared to OVH. As such, further studies on long-term clinical
outcomes are needed to reach a more precise cost-effectiveness
estimate.
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